

REFERENCIAS BIBLIOGRÁFICAS

ADA. American Diabetes Association. Standards of medical care in diabetes 2010. *Diabetes Care* 2010;33(s1):511-561.

Agrawal A, Simpson MJ, Black S, Carey MP, Samols D. A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal c-polysaccharide. *J Immunol* 2002;169(6):3217-3222.

Aguilar C, Gómez F, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. *Salud Publica Mex.* 2010;52(1):S44-S53

Aiello L. The potential role of PKC in diabetic retinopathy and macular edema. *Surv Ophthalmol* 2002;47(2):S263-S269.

Bailes R, Barbara K. Diabetes mellitus and its chronic complications. *AORN* 2002; 79(2):265-282.

Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. *WHO Bull* 2003;81:19-27.

Barzilay J, Abraham L, Heckbert S, Cushman M, Kuller L, Resnick H, Tracy R. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. *Diabetes* 2001;50(10):2384-2389.

Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem* 2004;279(47):48487-48490.

Bodí V, Sanchis J, Llàcer A, Insa L, Chorro F, López V. ST-segment elevation on q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction. *Am Heart J* 1999;137(6):1107-1115.

Bruno G, Fornengo P, Novelli G, Panero F, Perotto M, Segre O, Zucco Ch, Deambrogio P, Barger G, Cavallo P. C-reactive protein and 5-year survival in type 2 diabetes the casale monferrato study. *Diabetes* 2009;58:926-933.

Brustolin S, Giugliani R, Félix T. Genetics of homocysteine metabolism and associated disorders. *Brazilian J Med Biol Res* 2010;43(1):1-7.

Busch M, Franke S, Muller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. *Kidney Int* 2004;66:338-347.

Chandalia M, Chan A, Devaraj S, Jialal I, Grundy S, Abate N. Elevated plasma high-sensitivity c-reactive protein concentrations in Asian Indians living in the United States. *J Clin Endocrinol Metabolism* 2003;88(8):3773-3776.

Chang M, Binder Ch, Torzewski M, Witztum J. C- reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. *Proc Natl Acad Sci J* 2002;99(20):13043-13048.

Cho E, Kim E, Kim W, Jeong E, Koh E, Lee W, Kim M, Park J, Lee K. Homocysteine as a risk factor for development of microalbuminuria in type 2 diabetes. *Korean Diabetes J* 2010;34:200-206.

Cohen M, Ziyadeh F, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. *L Lab Clin* 2006;147(5):211-219.

Cook N, Buring J, Ridker P. The effect of including C-reactive protein in cardiovascular risk prediction models for women. *Ann Intern Med* 2006;145:21-29

Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. *J Atheroscler Thromb* 2010;17(1):1-11.

Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. *Mayo Clin Proc* 2008;83(3):333-342.

Danesh J, Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet*. 2010;375(9709):132-140.

Donnelly R, Emslie-Smith A, Gardner I, Morris A. ABC of arterial and venous disease vascular complications of diabetes. *BMJ* 2000;320:1062-1066.

Flores M, Barquera S, Carrión C, Rojas R, Villalpando S, Olaiz G, González C. Concentraciones de proteína c reactiva en adultos mexicanos: alta prevalencia de un factor de riesgo cardiovascular. *Salud Pública Mex* 2007;49(3):S348-S360.

Ford E, Giles W, Mokdad A, Myers G. Distribution and correlates of C-reactive protein concentrations among US adult women. *Clin Chem* 2004;50(3):574-581.

Ford E, Giles W, Myers G, Mannino D. Population distribution of high-sensitivity c-reactive protein among US men: findings from National Health and Nutrition Survey 1999-2000. *Clin Chem* 2003;49(4):686-689.

Freeman D, Norrie J, Caslake M, Gaw A, Ford I, Lowe G, O'Reilly D, Packard C. C-reactive protein is an independent predictor of risk of the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 2002;51:1596-1600.

García J. Estado oxidativo-metabólico y afectación retiniana en diabetes mellitus e hipertensión arterial. Seguimiento a cinco años. Tesis, Universidad de Valencia 2006. 61-67.

Gerhardinger C, Dagher Z, Sebastiani P, Seek Y, Lorenzi M. The transforming growth factor- β pathway is a common target of drugs that prevent experimental diabetic retinopathy. *Diabetes* 2009;58:1659-1667.

Goldberg R. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. *J Clin Endocrinol Metabol* 2009;94:3171-3182.

González E, Pascual I, Laclaustra M, Casanovas J. Síndrome metabólico y diabetes mellitus. *Rev Esp Cardiol Supl.* 2005;5:30D-37D.

Gregory W, Guttmancher E, McCarthy M. Genomics, type 2 diabetes, and obesity. *New Engl J Med* 2010;363:2339-2350.

Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P, Lokshin AE, Arslan AA. Reproducibility of serum cytokines and growth factors. *Cytokine* 2009;45(1):44-49.

Gugliucci A. Glicación de proteínas: rol protagónico de la hiperglicemia en las complicaciones crónicas de la diabetes mellitus. *Rev Med Uruguay* 2000;16:58-75.

Han T, Sattar N, Williams K, González C, Lean M, Haffner S. Prospective study of c-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico city diabetes study. *Diabetes Care* 2002;25(11):2016-2021.

Hubmacher D, Cirulis J, Miao M, Keeley F, Reinhardt D. Functional consequences of homocysteinylolation of the elastic fiber proteins fibrillin-1 and tropoelastin. *J Biol Chem* 2010;285(2):1188-1198.

Huffman F, Whisner S, Zarini G, Nath S. Waist circumference and BMI in relation to serum high sensitivity c-reactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes. *Int J Environ Res Public Health* 2010;7:842-852.

Izuta H, Matsunaga N, Shimazawa M, Sugiyama T, Ikeda T, Hara H. Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body. *Mol Vis* 2010;16:130-136.

Kaysen G. Biochemistry and biomarkers of inflamed patients: why look, what to assess. *Am Soc Nephrol* 2009;4:S56-S63.

King H, Aubert R, Herman W. Global Burden of diabetes, 1995-2025 prevalence, numerical estimates, and projections. *Diabetes Care* 1998;21(9):1414-1431.

King K, Jones J, Warthen J. Microvascular and macrovascular complications of diabetes mellitus. *Am J Pharmaceutical Edu* 2005;69(5):1-10.

Kuper H, Nicholson A, Kivimaki M, Aitsi A, Cavalleri G, Deanfield J, Heuschmann P, Jouven X, Malyutina S, Mayosi B, Sans S, Thomsen T, Witteman J, Hingorani A, Lawlor D, Hemingway H. Evaluating the causal relevance of diverse risk markers: horizontal systematic review. *BMJ* 2009;339:1-11.

Lakshmi S, Ravichand D. Dyslipidemia, C-reactive protein and leptin levels in non diabetic obese subjects. *Bangladesh liver J* 2009;1(1):41-50.

Ledue T, Weiner D, Sipe J, Poulin S, Collins M, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for c-reactive protein, serum amyloid a, and mannose-binding protein in human serum. *Ann Clin Biochem* 1998;35(6):745-753.

Lima L, Carvalho M, Soares A, Sabino A, Fernandes A, Novelli B, Sousa M. High-sensitivity c-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure. *Arq Bras Endocrinol Metab* 2007;51(6):956-960.

Mishra P, Tyagi N, Sen U, Joshua I, Tyagi S. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. *Cardiovasc Diabetol* 2010;9(49):1-13.

Nabipour I, Vahdat K, Jafari S, Beigi S, Assadi M, Azizi F, Sanjdideh Z. Elevated high sensitivity c-reactive protein is associated with type 2 diabetes mellitus: the Persian gulf healthy heart study. *Endocr J* 2008;55(4):717-722.

Nakamura M, Sato S, Shimamoto T. Establishment of external quality control program for hs-crp and three-year follow-up of the performance for precision and accuracy. *J Atheroscler Thromb.* 2007;14(6):287-293.

Nakano S, Kuboki K, Matsumoto T, Nishimura Ch, Yoshino G. Small, dense ldl and high-sensitivity c-reactive protein (hs-crp) in metabolic syndrome with type 2 diabetes mellitus. *Journal of Atherosclerosis and Thrombosis* 2010;17(4):410-415.

Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L, Ferrannini E. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. *Diabetes* 2006;55:1133-1140.

NCEP. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-3421.

Ng P, Le Saux A, Lee C, Tan N, Lu J, Thiel S, Ho B, Ding J. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. *EMBO J* 2007;26(14):3431-3440.

Norgaz T, Hobikoglu G, Aksu Huseyin, Guveli A, Aksoy S, Ozer O, Bolca O, Narin A. Retinopathy is related to the angiographically detected severity and extent of coronary artery disease in patients with type 2 diabetes mellitus. *Int Heart J* 2005; 46:639-646.

Norma Oficial Mexicana 015-SSA2-1994. <http://www.salud.gob.mx/unidades/cdi/nom/m015ssa24.html>.

Patti M, Virkamaki A, Landaker E, Kahn C, Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. *Diabetes* 1999;48:1562-1571.

Pearson T, Mensah G, Alexander R, Anderson J, Cannon R, Criqui M, Fald Y, Fortmann S, Hong Y, Myers G, Rifai N, Smith S, Taubert K, Tracy R, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. a statement for health care professionals from the centers for disease control and prevention and the american heart association. *Circulation* 2003;107:499-511.

Pepys M, Hirschfield G. C-reactive protein and cardiovascular disease: new insights from an old molecule. *Q J M* 2003;96(11):793-807.

Pepys M, Hirschfield G, Tennent G, Gallimore J, Kahan M, Bellotti B, Hawkins P, Myers R, Smith M, Polara A, Cobb A, Ley S, Aquilina J, Robinson C, Sharif I, Gray G, Sabin C, Jenvey M, Kolstoe S, Thompson D, Wood S. Targeting c-reactive protein for the treatment of cardiovascular disease. *Nature* 2006;440(10):1217-1221.

Piñon P, Kaski J. Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?. *Rev Esp Cardiol.* 2006;59(3):247-258.

Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 2001;286:327-334.

Preston G, Calle R. Elevated serum sorbitol and not fructose in type 2 diabetic patients. *Biomark Insights* 2010;5:33-38.

Pu L, Lu L, Wei X, Yan R, Sheng J, Hu J, Kun Z, Ding F, Chen Q, Sheng L, Shen J, Hong D, Feng W. Value of serum glycated albumin and high-sensitivity c-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. *Cardiovasc Diabetol* 2006;27(5):1-7.

Ramirez C, Martinez G, Lozano J, Olvera A, Higuera L, García E, Guido R, Castrejón I. Proteína c reactiva de alta afinidad como marcador inflamatorio. *Revista Alergia México* 2007;54(1):7-13.

Rascón-Pacheco R, Candia-Plata MC, Rivera B, Romero M, Brito O, Guerrero F. Geometric coding and cluster analysis to assess metabolic control of patients with type 2 diabetes mellitus. *Rev Panam Salud Publica* 2010;27(4):276-282.

Rato Q. Diabetes mellitus: a global health problem. *Rev Port Cardiol* 2010;29(04):539-543.

Reynoso N, Mehta R, Almeda P, Rojas R, Villalpando S, Hernández M, Aguilar C. Estimated incidence of cardiovascular complications related to type 2 diabetes in México using the UKPDS outcome model and a population-based survey. *Cardiovasc Diabetol* 2011;1:1-9.

Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, Koenig W, Libby P, Lorenzatti A, Macfadyen J, Nordestgaard B, Shepherd J, Willerson J, Glynn R.

Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. *N Engl J Med* 2008;359(21):2195-2207.

Ridker P, Rifai N, Rose L, Buring J, Cook N. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002;347(20):1557-1565.

Rivera J, Barquera S, Campirano F, Campos I, Safdie M, Tovar V. Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity. *Public Health Nutr* 2002;5(1A):113-122.

Schmidt M, Duncan B, Sharrett A, Lindberg G, Savage P, Offenbacher S, Azambuja M, Tracy R, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. *Lancet* 1999;353:1649-1652.

Shih H, Zhang S, Cao W, Hahn A, Wang J, Paulsen J, Harnish D. CRP is a novel ligand for the oxidized ldl receptor lox-1. *Am J Physiol Heart Circ Physiol* 2009; 296:H1643-H1650.

Smith G, Timpson N, Lawlor D. C-reactive protein and cardiovascular disease risk: still an unknown quantity? *Ann Intern Med* 2006;145:70-71.

Soinio M, Marniemi J, Laakso M, Lehto S, Ronnema T. High-sensitivity c-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. *Diabetes Care* 2006;29(2):329-333.

Stitt A. The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Exp Mol Pathol* 2003;75:95-108.

Stratton I, Alder A, Neil W, Matthews D, Manley S, Cull C, Hadden D, Turner R. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (ukpds 35): prospective observational study. *BMJ* 2000;321:405-412.

Tataranni P, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of over nutrition on type 2 diabetes? *Diabetes* 2005;54(4):917-927.

Vinik A, Maser R, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? *Diabetes Care* 2010;33(7):1688-1690.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047-1053.

Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837-1847.